Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-PSMA-1007
- Development stage
- Unknown
- Lead developer
- Centre for Probe Development and Commercialization
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
18F-PSMA-1007 is a fluorine-18 labeled radiopharmaceutical small molecule used as a diagnostic imaging agent for positron emission tomography (PET) in patients with prostate cancer. It specifically targets the prostate-specific membrane antigen (PSMA), a protein that is significantly overexpressed on the surface of prostate cancer cells. A key pharmacological feature of 18F-PSMA-1007 is its predominant hepatobiliary excretion, which minimizes urinary radioactivity in the bladder and ureters, thereby enhancing the clarity of imaging in the pelvic region and prostate bed. The Affiliated Hospital of Jiangnan University has conducted clinical trials to evaluate its efficacy in the diagnosis, staging, and monitoring of treatment response in prostate cancer patients, often comparing its performance to other tracers like 18F-FDG.
- Brand names
- radelumin
- Other names
- Fluorine-18-PSMA-1007Fluorine18-PSMA-1007Fluorine 18-PSMA-1007[18F]PSMA-1007
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 18F-PSMA-1007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-PSMA-1007.